ReviewCardiovascular toxicology2013
Cardiovascular autophagy: crossroads of pathology, pharmacology and toxicology.
Review in Cardiovascular toxicology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 58 citations in OpenAlex.
- Novel roles of Nrf3-Trim5 axis in vascular smooth muscle cell dysfunctions and neointimal hyperplasia.Cardiovascular research · 2025Article
- Tianxiangdan suppresses foam cell formation by enhancing lipophagy and reduces the progression of atherosclerosis.In vitro cellular & developmental biology. Animal · 2025Article
- Nanocurcumin in myocardial infarction therapy: emerging trends and future directions.Frontiers in bioengineering and biotechnology · 2024Review
- Adenosine 2 receptor regulates autophagy and apoptosis to alleviate ischemia reperfusion injury in type 2 diabetes via IRE-1 signaling.BMC cardiovascular disorders · 2023Article
- Caffeine prevents restenosis and inhibits vascular smooth muscle cell proliferation through the induction of autophagy.Autophagy · 2022Article
- Enhanced curcumin loaded nanocellulose: a possible inhalable nanotherapeutic to treat COVID-19.Cellulose (London, England) · 2022Article
- Recent Progress in Nanotechnology for COVID-19 Prevention, Diagnostics and Treatment.Nanomaterials (Basel, Switzerland) · 2021Review
- Autophagy in cardiovascular diseases: role of noncoding RNAs.Molecular therapy. Nucleic acids · 2021Review
- Encapsulated Food Products as a Strategy to Strengthen Immunity Against COVID-19.Frontiers in nutrition · 2021Review
- The Protective Effect of Cyanidin-3-Glucoside on Myocardial Ischemia-Reperfusion Injury through Ferroptosis.Oxidative medicine and cellular longevity · 2021Article
- Potential effects of curcumin in the treatment of COVID-19 infection.Phytotherapy research : PTR · 2020Review
- Vascular autophagy in health and disease.Basic research in cardiology · 2020Review
- Mechanism of interactions between endoplasmic reticulum stress and autophagy in hypoxia/reoxygenation‑induced injury of H9c2 cardiomyocytes.Molecular medicine reports · 2019Article
- As time flies by: Investigating cardiac aging in the short-lived Drosophila model.Biochimica et biophysica acta. Molecular basis of disease · 2019Review
- Clinorotation-induced autophagy via HDM2-p53-mTOR pathway enhances cell migration in vascular endothelial cells.Cell death & disease · 2018Article
- The Anti-atherosclerotic Effect of Paeonol against Vascular Smooth Muscle Cell Proliferation by Up-regulation of Autophagy via the AMPK/mTOR Signaling Pathway.Frontiers in pharmacology · 2017Article
- The roles of macrophage autophagy in atherosclerosis.Acta pharmacologica Sinica · 2016Review
- Pleiotropic Meta-Analyses of Longitudinal Studies Discover Novel Genetic Variants Associated with Age-Related Diseases.Frontiers in genetics · 2016Article
- Proteotoxicity and cardiac dysfunction.Circulation research · 2015Review
- Mitochondrial functional impairment in response to environmental toxins in the cardiorenal metabolic syndrome.Archives of toxicology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Cardiovascular disease (CVD) remains the leading cause of death worldwide, despite the significant advances in medicine. Autophagy, a process of self-cannibalization employed by mammalian cells for the recycling of cellular contents, is altered not only in a number of CVDs, but in other diseases, as well. Many FDA-approved drugs are known to induce autophagy-mediated side effects in the cardiovascular system. In some cases, such drug-induced autophagy could be harnessed and used for treating CVD, greatly reducing the duration and cost of CVD treatments. However, because the induction of autophagy in cardiovascular targets can be both adaptive and maladaptive under specific settings, the challenge is to determine whether the changes stimulated by drug-induced autophagy are, in fact, beneficial. In this review, we surveyed a number of CVDs in which autophagy is known to occur, and we also address the role of FDA-approved drugs for which autophagy-mediated side effects occur within the cardiovascular system. The therapeutic potential of using small molecule modulators of autophagy in the management of CVD progression is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.